← Peptide Database/Tirzepatide
MetabolicTier 1 β€” Strong clinical evidence (RCTs)

Tirzepatide

Mounjaro Β· Zepbound

Dual GIP/GLP-1 receptor agonist (first in class) with superior weight loss outcomes (~22% body weight) compared to semaglutide in head-to-head trials. FDA approved for T2 diabetes and obesity.

πŸ’‰ SC injection🧊 Refrigerate at 2–8Β°C; after first use keep at room temperature up to 21 days

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol β†’

Mechanism of Action

Activates both GIP and GLP-1 receptors, providing additive appetite suppression, glucose control, and enhanced fat oxidation via GIP's distinct metabolic pathways.

Clinical Applications

  • βœ“Type 2 diabetes (FDA approved β€” Mounjaro)
  • βœ“Obesity treatment (FDA approved β€” Zepbound)
  • βœ“Superior option when semaglutide provides insufficient response
  • βœ“Metabolic syndrome
  • βœ“NASH (clinical trials ongoing)

Dosing Protocol

Recommended Dosing

SC injection. Start 2.5 mg/week Γ— 4 weeks, then increase by 2.5 mg every 4 weeks to maximum 15 mg/week. Titrate to lowest effective dose.

Safety & Contraindications

Possible Side Effects

  • ⚠Nausea, vomiting, diarrhoea (similar to semaglutide)
  • ⚠Constipation
  • ⚠Hypoglycaemia (when used with insulin/sulphonylureas)
  • ⚠Pancreatitis (rare)
  • ⚠Thyroid C-cell risk

Contraindications

  • βœ•Personal or family history of medullary thyroid cancer
  • βœ•MEN2
  • βœ•Pancreatitis history
  • βœ•Pregnancy

Combinations & Synergies

πŸ”— BPC-157gut protection support
πŸ”— Semaglutidedo not combine
#metabolic#GLP-1#GIP#obesity#diabetes#weight-loss#FDA-approved
← Back to database